ArticleBrain communications2026
Predictive value of cerebrospinal fluid Alzheimer's disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson's disease.
Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment is a major non-motor feature of Parkinson's disease (PD). Alzheimer's disease CSF biomarkers-amyloid-β (Aβ42, Aβ42/40), phosphorylated tau (p-tau) and total tau (t-tau)-may influence both cognitive and motor outcomes, but their role in relation to Parkinson's disease phenotype or progression remains unclear. Moreover, few studies have investigated these associations using extensive neuropsychological batteries. The aim of the study was to examine the associations between CSF Alzheimer's disease biomarkers, domain-specific neuropsychological performance and motor impairment in Parkinson's disease and to evaluate their predictive value for longitudinal changes. Seventy-eight Parkinson's disease patients underwent extensive neuropsychological examination, along with motor evaluation and Alzheimer's disease CSF biomarkers quantification. Fifty-two patients completed follow-up motor assessment and 43 repeated cognitive evaluation after 18-24 months. Correlation and regression models adjusted for demographic and clinical covariates were applied. Thirty-nine patients were classified as mild cognitive impaired (PD-MCI), mostly with multidomain impairment. Amyloid-β biomarkers were associated with poorer attention, working memory, executive and language performance. Tau proteins were inversely associated with motor scores. PD-MCI patients tended to experience greater motor decline than cognitive unimpaired subjects. Over time, higher p-tau and t-tau predicted global cognitive decline (MMSE), while lower Aβ42/40 predicted worsening in verbal memory and reasoning. Higher t-tau and lower baseline MMSE independently predicted greater motor deterioration. CSF Alzheimer's disease biomarkers showed domain-specific relationships with cognitive function and predicted both neuropsychological decline and motor progression. Combining detailed neuropsychological profiling with Alzheimer's disease biomarkers assessment may improve identification of high-risk patients and support integrated biological definitions of Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.